Docetaxel is a semi-synthetic, second-generation taxane derived from the European yew tree (Taxus baccata). It is a potent antineoplastic agent that promotes microtubule assembly and stabilizes microtubules, inhibiting their depolymerization. This leads to cell cycle arrest in the G2/M phase and subsequent apoptosis. The 80mg single-dose vial is a standard presentation for adult dosing regimens, particularly in breast and non-small cell lung cancer protocols in India.
Adult: 60-100 mg/m² body surface area (BSA), administered as a one-hour intravenous infusion every 3 weeks. The 80mg vial is often used for a patient with a BSA of approximately 1.7-2.0 m² at the 75 mg/m² dose. Dose is calculated individually.
Note: 1. MUST be diluted in 250 mL of either 0.9% Sodium Chloride injection or 5% Dextrose injection. 2. Final concentration should be between 0.3 to 0.9 mg/mL. 3. Administer as a 1-hour IV infusion using a non-PVC (polyolefin) infusion set with an in-line filter (0.22 micron). 4. Premedicate with oral corticosteroids (e.g., Dexamethasone 8 mg twice daily for 3 days, starting 1 day before docetaxel). 5. Monitor vital signs during infusion for hypersensitivity reactions.
Docetaxel binds reversibly to the β-tubulin subunit of microtubules with high affinity. This binding promotes the assembly of stable, non-functional microtubule bundles and inhibits their normal dynamic reorganization, which is essential for vital interphase and mitotic cellular functions.
Pregnancy: Pregnancy Category D (as per US FDA). There is positive evidence of human fetal risk based on the drug's mechanism. Can cause fetal harm. Contraindicated in pregnancy. Women of childbearing potential must use effective contraception during and for at least 6 months after therapy.
Driving: May cause fatigue, dizziness, or neuropathy. Patients should be cautioned about driving or operating machinery if they experience these effects.
| Ketoconazole, Itraconazole, Voriconazole, Clarithromycin | Potent CYP3A4 inhibitors; increase docetaxel exposure and toxicity (myelosuppression). | Major |
| Rifampicin, Carbamazepine, Phenytoin, St. John's Wort | Potent CYP3A4 inducers; decrease docetaxel exposure, reducing efficacy. | Major |
| Other myelosuppressive chemotherapy (e.g., Doxorubicin, Cyclophosphamide) | Additive risk of severe neutropenia, anemia, thrombocytopenia. | Major |
| Live Vaccines (e.g., MMR, Varicella, Yellow Fever) | Risk of disseminated infection due to immunosuppression. | Major |